HC Wainwright restated their buy rating on shares of Oxford Biomedica (OTCMKTS:OXBDF) in a research report released on Wednesday morning, The Fly reports.
A number of other research analysts have also recently commented on OXBDF. Zacks Investment Research cut Oxford Biomedica from a buy rating to a hold rating in a research note on Wednesday, August 11th. Royal Bank of Canada reaffirmed an outperform rating on shares of Oxford Biomedica in a research note on Monday, June 21st. Finally, Panmure Gordon raised Oxford Biomedica from a hold rating to a buy rating in a research note on Wednesday, July 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Buy and a consensus target price of $21.00.
Oxford Biomedica stock opened at $21.39 on Wednesday. The firm has a market cap of $1.64 billion, a PE ratio of -213.90 and a beta of 1.16. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.06 and a quick ratio of 1.93. Oxford Biomedica has a one year low of $10.13 and a one year high of $22.86. The stock’s fifty day moving average price is $19.52 and its two-hundred day moving average price is $17.02.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.